06 August 2026
06 August 2026
Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.
Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
The new arrangement will extend the use of Schrödinger’s technologies, including Bunsen and RetroSynth, throughout BMS’s teams.
How evolving development priorities are helping organisations build manufacturing knowledge from the earliest stages of development.
Premium Content is our new free subscription that provides access to deeper analysis, data-led features and exclusive reports.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
